Well-designed research studies agree that ivermectin is not an effective way to treat or prevent COVID-19.
In this platform randomized trial conducted in the US between February and July 2022, treatment with ivermectin 600 ug/kg daily for 6 days did not improve time to sustained recovery among outpatients with mild to moderate COVID-19 compared to placebo.
In this platform randomized trial conducted in the US during a period of Delta and Omicron variant predominance, treatment with ivermectin, compared with placebo, did not significantly improve time to recovery among outpatients with mild to moderate COVID-19.
In this randomized clinical trial at a single site in Cali, Colombia, duration of COVID-19 symptoms was not significantly different for patients who received a 5-day course of ivermectin compared with placebo.
In this open-label randomized clinical trial of high-risk patients with COVID-19 in Malaysia, a 5-day course of oral ivermectin administered during the first week of illness did not reduce the risk of developing severe disease compared with standard of care alone.
In this meta-analysis of 12 randomized clinical trials testing the effects of ivermectin as a treatment for COVID-19, favorable mortality results were limited to trials in regions with high prevalence of strongyloidiasis, with no evidence that ivermectin had a mortality benefit in low-prevalence regions.
A trial that evaluated 3 existing generic medications鈥攎etformin, ivermectin, and fluvoxamine鈥攆or early outpatient treatment of SARS-CoV-2 infection among adults with overweight and obesity did not prevent progression to severe COVID-19.
In this pharmacoeconomic study, private and Medicare plans paid an estimated $2.5 million for ivermectin prescriptions in the week of August 13, 2021, extrapolated to $129.7 million annually, despite evidence suggesting ivermectin is ineffective for COVID-19.